Want to see GMAB full AI Analyst Report?
GMAB Stock Chart & Stats
$28.87
$0.08(0.28%)
At close: 4:00 PM EDT
$28.87
$0.08(0.28%)
Day’s Range― - ―
52-Week Range$22.48 - $35.43
Previous CloseN/A
Volume1.08M
Average Volume (3M)1.87M
Market Cap
$18.77B
Enterprise Value$20.72K
Total Cash (Recent Filing)$1.50B
Total Debt (Recent Filing)$5.27B
Price to Earnings (P/E)24.4
Beta0.70
Next Earnings
Nov 05, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding623,532,530
10 Day Avg. Volume1,891,251
30 Day Avg. Volume1,866,644
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)3.28
Price to Sales (P/S)5.14
P/FCF Ratio16.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.67Price Target Upside33.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.16
Revenue Forecast (FY)$4.45B
Bulls Say, Bears Say
Bulls Say
Diversified Commercial Revenue GrowthBroad-based H1 top-line expansion driven roughly equally by DARZALEX royalties and EPKINLY net sales demonstrates a diversified, partner-plus-proprietary revenue model. This reduces reliance on a single product, supports predictable royalties and commercial rollout funding, and underpins medium-term revenue resilience.
Clinical Validation For EpcoritamabA randomized Phase III PFS win materially strengthens epcoritamab’s clinical profile and franchise potential in B‑cell malignancies. Durable clinical proof increases likelihood of wider label adoption, stronger negotiating leverage with payers/partners, and sustained royalty streams across geographies over multiple years.
High Cash Conversion And ProfitabilityNear‑par FCF to net income signals strong earnings quality and internal financing capacity to fund launches and late‑stage programs without excessive dilution. Even if FCF growth has slowed, the existing cash conversion base supports sustained R&D investment and commercialization spend for the next several quarters.
Bears Say
Elevated LeverageLeverage near parity with equity materially reduces financial flexibility; higher debt raises interest and refinancing risk and limits capacity to fund costly confirmatory trials or absorb program setbacks without external capital, increasing structural financing vulnerability over months ahead.
Margin Compression And Weaker ProfitabilityMaterial margin erosion versus recent years shrinks the company’s buffer against commercialization costs or trial delays. Sustained compression could force slower reinvestment, tighter pricing or cost cuts, and reduce long‑term free cash flow generation and reinvestment ability over the coming 2–6 months.
Regulatory & Competitive Execution RiskImmature overall‑survival data and unresolved confirmatory pathways introduce durable regulatory timing and labeling risk that can delay or narrow market access. Coupled with crowded competitor landscapes in key indications, this can limit peak uptake and royalty duration for new assets.
Genmab News
GMAB FAQ
What was Genmab (Otc)’s price range in the past 12 months?
Genmab (Otc) lowest stock price was $22.48 and its highest was $35.43 in the past 12 months.
What is Genmab (Otc)’s market cap?
Genmab (Otc)’s market cap is $18.77B.
When is Genmab (Otc)’s upcoming earnings report date?
Genmab (Otc)’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Genmab (Otc)’s earnings last quarter?
Genmab (Otc) released its earnings results on Aug 06, 2026. The company reported $0.491 earnings per share for the quarter, beating the consensus estimate of $0.356 by $0.135.
Is Genmab (Otc) overvalued?
According to Wall Street analysts Genmab (Otc)’s price is currently Undervalued.
Does Genmab (Otc) pay dividends?
Genmab (Otc) does not currently pay dividends.
What is Genmab (Otc)’s EPS estimate?
Genmab (Otc)’s EPS estimate is 0.37.
How many shares outstanding does Genmab (Otc) have?
Genmab (Otc) has 623,532,530 shares outstanding.
What happened to Genmab (Otc)’s price movement after its last earnings report?
Genmab (Otc) reported an EPS of $0.491 in its last earnings report, beating expectations of $0.356. Following the earnings report the stock price went up 1.948%.
Which hedge fund is a major shareholder of Genmab (Otc)?
Currently, no hedge funds are holding shares in GMAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (33.93% Upside)
$38.67 (33.93% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
87.91%
Trailing 12-Months
Company Description
Genmab (Otc)
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
GMAB Company Deck
GMAB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Genmab presented a strongly positive commercial and financial performance in H1 2026 — double-digit revenue and operating profit growth, upgraded full-year guidance, robust Epkinly momentum, meaningful product sales (DARZALEX, EPKINLY, TIVDAK), and multiple late-stage clinical advances including a positive Phase III PFS readout and new Phase III initiations. The company also acknowledged execution uncertainties: several data readouts remain event-driven or immature (OS not yet mature), competition across key indications is intensifying, some trial timing/readout clarifications raised investor questions, and integration/IP/tax factors introduce near-term modeling uncertainty. On balance the operational and financial momentum and near-term catalyst calendar outweigh the challenges, supporting a constructive outlook.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$38.67
▲(33.93% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.76% Mutual Funds
0.26% Other Institutional Investors
97.69% Public Companies and
Individual Investors